Congress moves to cap drug prices at international levels, threatening pharma profits

What it does

This bill caps U.S. prescription drug prices at the average price charged in Canada, France, Germany, Italy, Japan, and the United Kingdom. Manufacturers that charge more than this international reference price face civil penalties equal to 10 times the price difference per unit sold. The bill requires drug makers to report their U.S. and foreign prices annually to the Department of Health and Human Services.

Why we flagged it

The bill's core mechanism is a price cap tied to international benchmarks, enforced through civil penalties. This is straightforward price regulation, not a subsidy, carve-out, or hidden rider—the title accurately describes the function.

What the text implies

• Manufacturers may respond by raising prices in reference countries to avoid the penalty, shifting the cost burden internationally rather than reducing it globally.
• The bill does not address rebates, discounts, or negotiated prices—only 'retail list price'—which may create incentives for manufacturers to shift revenue to rebate structures that bypass the cap.
• No explicit provision for generic or biosimilar drugs; the cap applies equally to all approved drugs, potentially affecting incentives for generic entry.
• The penalty is per-unit sold, not a lump sum; a blockbuster drug could face penalties in the billions, creating extreme financial pressure and potential supply-chain disruption.
• No transition period or phase-in; immediate compliance required upon enactment, which may trigger rapid price adjustments or market withdrawal of certain drugs.

Who it affects

Ordinary Americans pay significantly higher drug prices than patients in other wealthy nations. This bill directly lowers the price ceiling for prescription drugs, reducing out-of-pocket costs and insurance premiums for patients. The penalty structure creates a strong financial incentive for manufacturers to comply, making lower prices enforceable.

Who stands to gain

• patients and consumers (lower drug costs)
• health insurance companies (lower claims costs)
• pharmacy benefit managers (lower acquisition costs)

Named in the bill

Department of Health and Human Services (HHS), Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), Canada, France, Germany, Italy, Japan, United Kingdom — and 3 more

Where it stands

1 cosponsor: 1 Democrats.

• May 5, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 5, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $840,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Josh Hawley, the sponsor, reported $68,000 in PAC receipts in the 2026 cycle.

• Grifols Shared Services North America Inc — $840,000 on 2 filings

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.